Haichuang Pharmaceutical Investor Relations Activity Record Form (September 2024)
Voluntary disclosure announcement on the approval of the US FDA for clinical trial application of HP515 tablets for the treatment of metabolic steatohepatitis (MASH)
CITIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Haichuang Pharmaceutical Co., Ltd.
Announcement on attending the 2024 Semi-Annual Science and Technology Innovation Board Special Group Results Briefing on Pharmaceuticals and Biological Products
Notice on voluntary disclosure of the clinical trial of HP515 tablets for the treatment of non-alcoholic steatohepatitis to obtain a drug clinical trial approval notice
Announcement of Resolution of the Fifth Meeting of the Second Board of Supervisors.
Announcement of Resolutions of the Sixth Meeting of the Second Board of Directors.
Special report on the use of funds raised during the first half of 2024.
Announcement of voluntary disclosure of clinical trial approval notice for drug clinical trial of HP560 tablets used for the treatment of myelofibrosis (myeloproliferative tumor)
Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.
Investor Relations Activity Record Form of Haichuang Pharmaceutical (June 17-26, 2024)
Announcement on the resignation of senior management personnel and adjustment of core technical personnel
CITIC Securities Co., Ltd.'s inspection opinion on the departure of core technicians of Haichuang Pharmaceutical Co., Ltd.
Haichuang Pharmaceutical Investor Relations Activity Record Form (May 15 to May 21, 2024)
Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Group Performance Briefing and the First Quarter 2024 Results Briefing
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Haichuang Pharmaceutical Co., Ltd.
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Site Inspection Report on Haichuang Pharmaceutical Co., Ltd.
Report on the work of the Board of Supervisors for the year 2023
Announcement on the company's 2024 related transaction forecast
Special report on the storage and actual use of funds raised in 2023
No Data
No Data